Gilead Sciences Work in process increased by 29.1% to $1.34B in Q3 2025 compared to the prior quarter. Year-over-year, this metric grew by 96.1%, from $684.00M to $1.34B. Over 4 years (FY 2020 to FY 2024), Work in process shows a downward trend with a -3.5% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.
An increase may indicate production bottlenecks or scaling efforts, while a decrease suggests efficient throughput or reduced manufacturing activity.
Represents the value of goods that have entered the production process but are not yet finished. For a manufacturer like...
Peers in medical device manufacturing typically maintain lean WIP levels to optimize cash conversion cycles.
inv_work_in_progress| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $924.00M | $727.00M | $590.00M | $540.00M | $484.00M | $430.00M | $577.00M | $570.00M | $622.00M | $614.00M | $847.00M | $778.00M | $803.00M | $684.00M | $847.00M | $1.08B | $1.04B | $1.34B |
| QoQ Change | — | -21.3% | -18.8% | -8.5% | -10.4% | -11.2% | +34.2% | -1.2% | +9.1% | -1.3% | +37.9% | -8.1% | +3.2% | -14.8% | +23.8% | +27.0% | -3.4% | +29.1% |
| YoY Change | — | — | — | — | -47.6% | -40.9% | -2.2% | +5.6% | +28.5% | +42.8% | +46.8% | +36.5% | +29.1% | +11.4% | +0.0% | +38.3% | +29.4% | +96.1% |
| % of Inventories | 76.0% | 64.9% | 36.5% | 45.2% | 44.2% | 37.8% | 38.3% | 39.7% | 40.2% | 39.9% | 47.4% | 51.5% | 59.0% | 43.7% | 49.5% | 53.3% | 49.8% | 51.5% |
| Share Change | — | -11.1pp | -28.4pp | +8.8pp | -1.0pp | -6.5pp | +0.5pp | +1.5pp | +0.5pp | -0.3pp | +7.5pp | +4.1pp | +7.4pp | -15.3pp | +5.9pp | +3.8pp | -3.5pp | +1.8pp |
We use cookies for analytics. See our Privacy and Cookie Policy.